Forecast
There is no analyst data available for this company.
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
In the last quarter, ADVICENNE (PROM.) EO-,20 had revenue of €2.88M and net profit of €4.62M
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 2.88M | - |
| Gross profit | -3.03M | - |
| Net profit | 4.62M | - |
| EBITDA | 5.88M | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €9.17M |
Number of shares | 14.55M |
52-week high/low | €2.35 - €0.61 |
| Dividends | No |
Beta | 0.96 |
P/E ratio | 211.43 |
PEG ratio | 2.11 |
P/B ratio | -0.42 |
P/S ratio | 1.63 |
Company profile
Advicenne S.A. develops therapeutics for the treatment of rare kidney diseases. Its lead product candidate is ADV7103 for the treatment of distal renal tubular acidosis in children and adults, as well as for the treatment of cystinuria, an inherited renal tubulopathy. The company also provides ADV6209, an oral liquid solution for children to reduce anxiety and to improve their immobility. Advicenne S.A. was founded in 2007 and is based in Paris, France.
| Name | ADVICENNE (PROM.) EO-,20 |
| CEO | Didier Laurens |
| Headquarters | Paris,
if France |
| Website | |
| IPO | 12/06/2017 |
| Employees | 11 |
Deep Dive
Ticker symbols
| Exchange | Symbol |
|---|---|
Euronext | ALDVI.PA |
Euronext | ADVIC.PA |
Frankfurt | 3MM.F |
Paris | ALDVI.PA |
München | 3MM.MU |
Düsseldorf | 3MM.DU |